Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer

NCT02323737 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

DRUG: Irinotecan and cisplatin
DRUG: Etoposide and cisplatin

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]